TMCnet News
Pennystockchaser.com: www.pennnystockchaser.com: Penny Stock Chaser Alerts, December 10, 2009: BRLI, EBIX, VCRT and TRGT(M2 PressWIRE Via Acquire Media NewsEdge) Pennystockchaser.com Alerts include BioReference Laboratories, Inc. (NASDAQ: BRLI); Ebix, Inc. (NASDAQ: EBIX); Vicor Technologies, Inc. (OTCBB: VCRT) and Targacept, Inc. (NASDAQ: TRGT) -- December 10, 2009 BioReference Laboratories, Inc. (NASDAQ: BRLI) trading at $33.36 on a volume of 20,629 shares ELMWOOD PARK, N.J., Dec 10, 2009 -- BioReference Laboratories, Inc. (NASDAQ: BRLI) announced today it plans to issue earnings results for the fourth quarter and year end of fiscal 2009 before the open of market trading on Thursday, December 17, 2009. The Company's earnings conference call is to take place the same day at 10:30 a.m. EST. The call will be hosted by Marc D. Grodman M.D., President and Chief Executive Officer. About BioReference Laboratories, Inc. BRLI is the third largest full service laboratory in the United States and the largest independent regional laboratory in the Northeastern market, primarily a clinical testing lab servicing physician offices with concentrations in the focused markets of esoteric testing, molecular diagnostics, anatomical pathology and correctional health care. BRLI operates as a national oncology laboratory under its GenPath label. Better science, superior technology and better service have enabled GenPath to earn a reputation as one of the premier hematopathology laboratories in the country. BRLI's innovative technology platform for sexually transmitted infections has enabled it to expand as a national laboratory in the area of Women's Health. GeneDx, a wholly owned subsidiary, is the BRLI genetics laboratory and is typically recognized as the leading laboratory for testing of rare genetic diseases; GeneDx has now become a technology leader with GenomeDx, based on a CGH array platform and its NextGen sequence offerings that are currently offered in cardiology and will be offered in the future in other disease specific areas. -- December 10, 2009 Ebix, Inc. (NASDAQ: EBIX) trading at $50.05 on a volume of 105,815 shares. ATLANTA, Dec 10, 2009 -- Ebix, Inc. (NASDAQ: EBIX), a leading international supplier of On-Demand software and E-commerce services to the insurance industry, today released the summary highlights from the investor meeting at the NASDAQ Marketsite building in New York. 85 analysts & investors, 21 Ebix senior Executives in addition to the EBIX CEO, CFO and three of the independent Ebix Board members attended the meeting and received the opportunity to interact with the senior management, Ebix CFO and the CEO. About Ebix A leading international supplier of On-Demand software and E-commerce services to the insurance industry, Ebix, Inc., (NASDAQ:EBIX) provides end to end solutions ranging from infrastructure Exchanges, carrier systems, agency systems and BPO services to custom software development for all entities involved in the insurance industry. -- December 10, 2009 Vicor Technologies, Inc. (OTCBB: VCRT) trading at $0.60 on a volume of 25,600 shares BOCA RATON, FL, Dec 10, 2009 -- David H. Fater, CEO of Vicor Technologies, Inc. (OTCBB: VCRT), today announced that its PD2i(R) nonlinear algorithm has been selected by Dr. Sanjay Sharma to be used in a month-long cardiac screening initiative to be held in South East London in April 2010. Vicor Technologies is a biotechnology company focused on the commercialization of innovative, non-invasive medical devices and diagnostics using its patented, proprietary PD2i(R) nonlinear algorithm and software to stratify patients at risk of sudden cardiac death or autonomic dysfunction, and trauma victims in need of lifesaving intervention. About Vicor Technologies, Inc. Vicor Technologies is a development-stage biotechnology company creating innovative non-invasive diagnostics employing its patented, proprietary point correlation dimension algorithm (PD2i(R)). The PD2i(R) nonlinear algorithm is a deterministic, nonlinear measure of electrophysiological potentials to predict future pathological events with a high degree of accuracy in target populations. -- December 10, 2009 Targacept, Inc. (NASDAQ: TRGT) closed at $23.34 on a volume of 284,839 shares. WINSTON-SALEM, N.C., Dec 10, 2009 -- Targacept, Inc. (NASDAQ: TRGT), a clinical-stage biopharmaceutical company developing a new class of drugs known as NNR Therapeutics(TM), today announced that it has initiated a Phase 2 clinical proof of concept trial of TC-5619 in cognitive dysfunction in schizophrenia. TC-5619 is a novel small molecule that is highly selective for the alpha7 neuronal nicotinic receptor, or NNR, and was discovered by Targacept scientists using Targacept's proprietary drug discovery platform known as Pentad(TM). About Targacept Targacept is a clinical-stage biopharmaceutical company that discovers and develops NNR Therapeutics(TM), a new class of drugs for the treatment of central nervous system diseases and disorders, in support of its vision of building health and restoring independence for patients. Targacept's product candidates selectively modulate neuronal nicotinic receptors that serve as key regulators of the nervous system to promote therapeutic effects and limit adverse side effects. Targacept has clinical-stage product candidates in development for major depressive disorder, attention deficit/hyperactivity disorder, Alzheimer's disease and cognitive dysfunction in schizophrenia, as well as multiple preclinical programs. Targacept recently announced a global collaboration and license agreement with AstraZeneca for the late-stage investigational product TC-5214 for the treatment of major depressive disorder. Targacept also has a cognition-focused collaboration with AstraZeneca and a strategic alliance with GlaxoSmithKline. Targacept's news releases are available on its website at www.targacept.com. About PennyStockChaser.com PennyStockChaser.com's alerts are daily e-mail on stocks that are hot in the market. These include stocks with huge volume, penny stocks, new 52 weeks high or lows, stocks with technical indicators and much more. Our stock alerts have done very well in the last couple of weeks. PennyStockChaser.com is a leading stock website that provides free daily alerts on stocks that are moving up. PennyStockChaser.com also tracks small cap stocks that are on the brink of exploding. We also feature companies on our website with research report, analysis, and newsletters. To feature a company on our web site please contact us at [email protected] PennyStockChaser.com is an independent electronic publication that provides information on selected publicly traded companies. PennyStockChaser.com is not a registered investment advisor or broker-dealer. PennyStockChaser.com's affiliates, officers, directors and employees may buy and sell additional shares in any company mentioned herein and may profit in the event those shares rise in value. Please do your own Due Diligence before investing in any of the stocks mentioned above. ((Comments on this story may be sent to [email protected])) (c) 2009 M2 COMMUNICATIONS |